Literature DB >> 8706284

Pituitary apoplexy after leuprolide administration for carcinoma of the prostate.

A Morsi1, S Jamal, J D Silverberg.   

Abstract

The syndrome of pituitary apoplexy has been reported to occur after the administration of several different medications. We report a case in which pituitary apoplexy developed shortly after the administration of leuprolide in a patient with prostate cancer. Leuprolide is a potent gonadotrophin releasing hormone (GnRH) analogue used to suppress leuteotrophic hormone (LH) and testosterone levels in patients with metastatic prostate cancer. LH and testosterone levels actually rise in the first week after its administration before becoming suppressed. We suspect that this acute stimulating effect of leuprolide is linked to the acute onset of pituitary apoplexy in a patient with a possible gonadotrophoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706284     DOI: 10.1046/j.1365-2265.1996.644465.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Pituitary apoplexy probably due to TRH and GnRH stimulation tests in a patient with acromegaly.

Authors:  H S Dökmetaş; A Selçuklu; R Colak; K Unlühizarci; F Bayram; F Keleştimur
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Pituitary apoplexy: a rare complication of leuprolide therapy in prostate cancer treatment.

Authors:  Georges Tanios; Nicolas Andrews Mungo; Aaysha Kapila; Kailash Bajaj
Journal:  BMJ Case Rep       Date:  2017-07-14

3.  Gonadotropin-releasing hormone-induced partial empty sella clinically mimicking pituitary apoplexy in a woman with a suspected non-secreting macroadenoma.

Authors:  L Foppiani; S Piredda; R Guido; R Spaziante; M Giusti
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

4.  Pituitary apoplexy after leuprolide.

Authors:  Anu Davis; Shefali Goel; Michalis Picolos; Min Wang; Victor Lavis
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 5.  Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.

Authors:  Yannis Guerra; Evelyn Lacuesta; Francisco Marquez; P B Raksin; Manuel Utset; Leon Fogelfeld
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

Review 6.  Apoplexy in nonfunctioning pituitary adenomas.

Authors:  Luiz Eduardo Wildemberg; Andrea Glezer; Marcello D Bronstein; Mônica R Gadelha
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

7.  The presence of a pituitary tumor in patients with prostate cancer is not a contraindication for leuprolide therapy.

Authors:  Angela Babbo; George T Kalapurakal; Benjamin Liu; Sanija Bajramovic; James P Chandler; John Garnett; John A Kalapurakal
Journal:  Int Urol Nephrol       Date:  2014-04-06       Impact factor: 2.370

8.  Pituitary apoplexy induced by gonadotropin-releasing hormone agonist administration: a rare complication of prostate cancer treatment.

Authors:  Mariana Barbosa; Sílvia Paredes; Maria João Machado; Rui Almeida; Olinda Marques
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-06-04

9.  Pituitary apoplexy induced by Gonadotropin-releasing hormone agonists for treating prostate cancer-report of first Asian case.

Authors:  Tsung-Yi Huang; Jih-Pin Lin; Ann-Shung Lieu; Yi-Ting Chen; Hung-Sheng Chen; Mei-Yu Jang; Jung-Tsung Shen; Wen-Jeng Wu; Shu-Pin Huang; Yung-Shun Juan
Journal:  World J Surg Oncol       Date:  2013-10-02       Impact factor: 2.754

10.  Gonadotropin-releasing hormone agonist-induced pituitary apoplexy.

Authors:  Fergus Keane; Aoife M Egan; Patrick Navin; Francesca Brett; Michael C Dennedy
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.